| Primary Device ID | B141QANGIOXA730 |
| NIH Device Record Key | 35971f89-3f4e-466f-abfb-2cfec8e9b3f9 |
| Commercial Distribution Status | In Commercial Distribution |
| Brand Name | QAngio XA |
| Version Model Number | 7.3 |
| Company DUNS | 549961191 |
| Company Name | Medis Medical Imaging Systems B.V. |
| Device Count | 1 |
| DM Exempt | false |
| Pre-market Exempt | false |
| MRI Safety Status | Labeling does not contain MRI Safety Information |
| Human Cell/Tissue Product | false |
| Device Kit | false |
| Device Combination Product | false |
| Single Use | false |
| Lot Batch | false |
| Serial Number | true |
| Manufacturing Date | true |
| Expiration Date | false |
| Donation Id Number | false |
| Contains Natural Rubber Latex | false |
| Labeled No Natural Rubber Latex | false |
| RX Perscription | true |
| OTC Over-The-Counter | false |
| Phone | +31715241700 |
| support@medis.nl | |
| Phone | +31715241700 |
| support@medis.nl | |
| Phone | +31715241700 |
| support@medis.nl | |
| Phone | +31715241700 |
| support@medis.nl | |
| Phone | +31715241700 |
| support@medis.nl | |
| Phone | +31715241700 |
| support@medis.nl | |
| Phone | +31715241700 |
| support@medis.nl | |
| Phone | +31715241700 |
| support@medis.nl | |
| Phone | +31715241700 |
| support@medis.nl | |
| Phone | +31715241700 |
| support@medis.nl | |
| Phone | +31715241700 |
| support@medis.nl | |
| Phone | +31715241700 |
| support@medis.nl | |
| Phone | +31715241700 |
| support@medis.nl | |
| Phone | +31715241700 |
| support@medis.nl | |
| Phone | +31715241700 |
| support@medis.nl |
| Device Issuing Agency | Device ID |
|---|---|
| HIBCC | B141QANGIOXA730 [Primary] |
| LLZ | System, Image Processing, Radiological |
| Steralize Prior To Use | false |
| Device Is Sterile | false |
| Public Version Status | Update |
| Device Record Status | Published |
| Public Version Number | 3 |
| Public Version Date | 2018-07-06 |
| Device Publish Date | 2016-06-13 |
| B141MEDISSUITEMRCT20250 - Medis Suite MRCT | 2025-05-22 Medis Suite MRCT is indicated for use in clinical settings where more reproducible than manually derived quantified results are |
| B141MEDISSUITEMRCT20230 - Medis Suite MRCT | 2023-06-13 Medis Suite MRCT 2023 is indicated for use in clinical settings where more reproducible than manually derived quantified results |
| B141MEDISSUITEXA20230 - Medis Suite XA | 2023-06-13 Medis Suite XA 2023 is indicated for use in clinical settings where validated and reproducible quantified results are needed to |
| B141MEDISSUITEMRCT20220 - Medis Suite MRCT | 2022-05-24 Medis Suite MRCT 2022 is indicated for use in clinical settings where more reproducible than manually derived quantified results |
| B141MEDISSUITEXA20220 - Medis Suite XA | 2022-05-24 Medis Suite XA 2022 is indicated for use in clinical settings where validated and reproducible quantified results are needed to |
| B141MEDISSUITEMRCT20210 - Medis Suite MRCT | 2021-10-19 Medis Suite MRCT 2021 is indicated for use in clinical settings where more reproducible than manually derived quantified results |
| B141MEDISSUITEXA20210 - Medis Suite XA | 2021-10-19 Medis Suite XA is indicated for use in clinical settings where validated and reproducible quantified results are needed to suppo |
| B141MEDISSUITEMRCT20200 - Medis Suite MRCT | 2020-09-21 Medis Suite MRCT is indicated for use in clinical settings where more reproducible than manually derived quantified results are |